Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 12/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.36 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.34 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.34 |
| ▸ | GNPAT | O15228 | 1/20 | 0.33 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8177335 | 0.85 | TGM2 (0.55) | TGM2FOLH1ZDHHC20ZDHHC2 | |
| SCHEMBL8184648 | 0.84 | TGM2 (0.45) | TGM2FOLH1ZDHHC20ZDHHC2GNPAT | |
| SCHEMBL7628303 | 0.84 | TGM2 (0.45) | TGM2FOLH1ZDHHC20ZDHHC2GNPAT | |
| SCHEMBL8177277 | 0.81 | C3AR1 (0.48) | TGM2FOLH1GNPATC3AR1 | |
| SCHEMBL14601343 | 0.80 | TGM2 (0.60) | TGM2FOLH1ZDHHC20ZDHHC2 | |
| SCHEMBL31623005 | 0.73 | FOLH1 (0.50) | TGM2FOLH1GNPAT | |
| SCHEMBL1562504 | 0.73 | TGM2 (0.50) | TGM2FOLH1ZDHHC20ZDHHC2 | |
| SCHEMBL8186011 | 0.73 | TGM2 (0.50) | TGM2FOLH1ZDHHC20ZDHHC2 | |
| SCHEMBL20310546 | 0.72 | TGM2 (0.53) | TGM2FOLH1ZDHHC20ZDHHC2 | |
| SCHEMBL974614 | 0.72 | FOLH1 (0.57) | TGM2FOLH1GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070009441-A1 | Biodegradable nanoparticles | MOLECULAR THERAPEUTICS, INC. (US) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070009441-A1 | Biodegradable nanoparticles | CD47, CD63, ECPAS | TGM2 3271/4885FOLH1 83/4885ZDHHC20 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.